Johnson & Johnson Yönetim
Yönetim kriter kontrolleri 2/4
Johnson & Johnson CEO'su Joaquin Duato, Jan2022 tarihinde atandı, in görev süresi 4.33 yıldır. in toplam yıllık tazminatı $ 32.76M olup, şirket hissesi ve opsiyonları dahil olmak üzere 4.9% maaş ve 95.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.015% ine doğrudan sahiptir ve bu hisseler $ 82.56M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.4 yıl ve 5.9 yıldır.
Anahtar bilgiler
Joaquin Duato
İcra Kurulu Başkanı
US$32.8m
Toplam tazminat
| CEO maaş yüzdesi | 4.88% |
| CEO görev süresi | 4.3yrs |
| CEO sahipliği | 0.01% |
| Yönetim ortalama görev süresi | 6.4yrs |
| Yönetim Kurulu ortalama görev süresi | 5.9yrs |
Son yönetim güncellemeleri
Recent updates
Seeking Alpha • 3h
Johnson & Johnson: A Dividend King, But Priced Appropriately, Big Conference Slate
Summary Johnson & Johnson is rated Hold, trading near intrinsic value with limited upside based on a 20x multiple and $12 normalized EPS. Q1 results showed 10% sales growth and a $450M revenue beat, with management raising FY 2026 guidance and extending the dividend growth streak to 64 years. JNJ faces headwinds from biosimilar and generic competition, MedTech challenges, and commercial sluggishness, but maintains strong FCF yield and a robust product pipeline. Technicals are mixed but lean bullish, with $235 as near-term resistance and investors advised to monitor upcoming conference commentary and sector momentum. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.Anlatı Güncellemesi • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.Anlatı Güncellemesi • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.
Yeni Anlatı • Mar 30
Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution
Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.Anlatı Güncellemesi • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
Yeni Anlatı • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.Anlatı Güncellemesi • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.Anlatı Güncellemesi • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.Anlatı Güncellemesi • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
Yeni Anlatı • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Jan 09
JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward
Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.Anlatı Güncellemesi • Dec 19
JNJ Future Portfolio Separation And Litigation Resolution Will Shape Balanced Risk Reward Outlook
Analysts have raised their average price target on Johnson & Johnson by about $7 to roughly $209, reflecting slightly faster expected revenue growth, a modestly higher future earnings multiple, and confidence that portfolio reshaping and pipeline execution can offset near term margin pressure. Analyst Commentary Street research on Johnson & Johnson has turned incrementally more constructive, with multiple firms lifting price targets in response to stronger fundamentals and portfolio actions that are viewed as supportive of a faster growth profile.Anlatı Güncellemesi • Dec 05
JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance
The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.Anlatı Güncellemesi • Nov 21
JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance
Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.Anlatı Güncellemesi • Nov 05
JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance
Johnson & Johnson's fair value estimate has increased by $1.52 to $199.56, as analysts point to improving core growth metrics, recent strong quarterly results, and expectations for higher margins following portfolio changes. Analyst Commentary Recent Street research reveals a mix of optimism and caution among analysts following Johnson & Johnson’s latest results, portfolio changes, and evolving sector dynamics.Anlatı Güncellemesi • Oct 22
Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments
Analysts have raised their fair value price target for Johnson & Johnson from approximately $185.13 to $198.03. They cite robust quarterly results, upcoming product launches, and anticipated growth and margin improvements from the company's business transformation initiatives as key reasons for the adjustment.CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 29 2026 | n/a | n/a | US$21b |
| Dec 28 2025 | US$33m | US$2m | US$27b |
| Sep 28 2025 | n/a | n/a | US$25b |
| Jun 29 2025 | n/a | n/a | US$23b |
| Mar 30 2025 | n/a | n/a | US$22b |
| Dec 29 2024 | US$24m | US$2m | US$14b |
| Sep 29 2024 | n/a | n/a | US$15b |
| Jun 30 2024 | n/a | n/a | US$16b |
| Mar 31 2024 | n/a | n/a | US$17b |
| Dec 31 2023 | US$28m | US$2m | US$13b |
| Oct 01 2023 | n/a | n/a | US$12b |
| Jul 02 2023 | n/a | n/a | US$12b |
| Apr 02 2023 | n/a | n/a | US$11b |
| Jan 01 2023 | US$13m | US$1m | US$16b |
| Oct 02 2022 | n/a | n/a | US$18b |
| Jul 03 2022 | n/a | n/a | US$17b |
| Apr 03 2022 | n/a | n/a | US$20b |
| Jan 02 2022 | US$14m | US$1m | US$18b |
| Oct 03 2021 | n/a | n/a | US$18b |
| Jul 04 2021 | n/a | n/a | US$18b |
| Apr 04 2021 | n/a | n/a | US$15b |
| Jan 03 2021 | n/a | n/a | US$15b |
| Sep 27 2020 | n/a | n/a | US$17b |
| Jun 28 2020 | n/a | n/a | US$15b |
| Mar 29 2020 | n/a | n/a | US$17b |
| Dec 29 2019 | US$13m | US$970k | US$15b |
Tazminat ve Piyasa: Joaquin 'nin toplam tazminatı ($USD 32.76M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 14.84M ).
Tazminat ve Kazançlar: Joaquin şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.
CEO
Joaquin Duato (62 yo)
4.3yrs
Görev süresi
US$32,758,111
Tazminat
Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Chairman | 4.3yrs | US$32.76m | 0.015% $ 82.6m | |
| Executive VP & CFO | 7.8yrs | US$14.41m | 0.0035% $ 19.7m | |
| Executive VP & Worldwide Chairman of Innovative Medicine | 14.3yrs | US$14.03m | 0.0081% $ 45.1m | |
| Executive Vice President of Innovative Medicine and R&D | 3.1yrs | US$12.21m | 0.0010% $ 5.7m | |
| Executive VP & Worldwide Chairman of MedTech | 2.6yrs | US$9.34m | 0.0011% $ 6.1m | |
| Controller & Chief Accounting Officer | 6.4yrs | Veri yok | 0.0010% $ 5.7m | |
| Executive VP & Chief Information Officer | 6.5yrs | Veri yok | 0.0011% $ 6.0m | |
| Chief Compliance Officer | no data | Veri yok | Veri yok | |
| Executive VP & Chief Legal Officer | 3.6yrs | Veri yok | 0.00098% $ 5.5m | |
| Executive VP & Chief Human Resources Officer | no data | Veri yok | 0.00082% $ 4.6m | |
| Group Chairman of MD&D Business - EMEA | no data | Veri yok | Veri yok | |
| Executive VP and Chief Technical Operations & Risk Officer | 7.8yrs | Veri yok | 0.0048% $ 26.6m |
6.4yrs
Ortalama Görev Süresi
58.5yo
Ortalama Yaş
Deneyimli Yönetim: JNJ 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Chairman | 4.3yrs | US$32.76m | 0.015% $ 82.6m | |
| Director | less than a year | US$59.13k | 0.000080% $ 446.3k | |
| Independent Director | 6.4yrs | US$367.55k | 0.00021% $ 1.2m | |
| Lead Independent Director | 7.1yrs | US$413.00k | 0.00012% $ 669.4k | |
| Independent Director | 3.3yrs | US$344.00k | 0.000010% $ 55.8k | |
| Independent Director | 12.6yrs | US$330.00k | 0% $ 0 | |
| Independent Director | 10.9yrs | US$375.00k | 0% $ 0 | |
| Independent Director | 8.1yrs | US$370.00k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$347.16k | 0.000010% $ 55.8k | |
| Independent Director | 6.4yrs | US$355.00k | 0.000040% $ 223.1k | |
| Director | less than a year | US$62.50k | Veri yok | |
| Independent Director | 5.4yrs | US$350.00k | 0% $ 0 |
5.9yrs
Ortalama Görev Süresi
62.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: JNJ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.9 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 22:30 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/29 |
| Yıllık Kazançlar | 2025/12/28 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Johnson & Johnson 53 Bu analistlerden 23, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |